10-Q: Kyverna Therapeutics Amends Loan Agreement, Advances Clinical Trials

Kyverna Therapeutics announced a First Amendment to its Loan and Security Agreement, extending loan availability and outlining new covenants, while also providing updates on its CAR T therapies for autoimmune diseases.

Summary

• Kyverna Therapeutics entered into a First Amendment to its Loan and Security Agreement with Oxford Finance LLC, effective June 30, 2026.
• The amendment extends the availability of the remaining $15.0 million of Term A Loans through December 31, 2026, in exchange for a $187,500 fee.
• New non-utilization fees and potential modifications to Term B and Term C loan availability are outlined, contingent on full Term A loan drawdowns.
• The company reported a net loss of $38.3 million for the three months ended June 30, 2026, and $78.0 million for the six months ended June 30, 2026.
• Research and development expenses decreased by 31% for the three months ended June 30, 2026, primarily due to lower CMO activities.
• General and administrative expenses increased by 72% for the three months ended June 30, 2026, driven by personnel and IT consulting costs.
• Kyverna received RMAT designation for miv-cel in SPS and MG, and is advancing rolling BLA submission for SPS.
• The company expects its current cash, cash equivalents, and marketable securities to fund operations for at least the next 12 months.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as cautiously optimistic, reflecting progress in clinical trials and regulatory pathways, but with ongoing financial needs and inherent risks in drug development.

Positives

• Extension of Term A loan availability through December 31, 2026, providing continued access to capital.
• Positive progress in clinical trials for miv-cel in Stiff Person Syndrome (SPS) and Myasthenia Gravis (gMG), with positive topline data presented.
• FDA alignment on the regulatory path for miv-cel in SPS, including a rolling BLA submission.
• Received RMAT designation for miv-cel in SPS and MG, facilitating increased FDA engagement.
• Entered into a clinical and commercial supply agreement with ElevateBio BaseCamp, Inc. for miv-cel manufacturing.
• Cash and cash equivalents and available-for-sale marketable securities totaled $199.4 million as of June 30, 2026, expected to fund operations for at least 12 months.

Negatives

• Continued significant net losses, with a $38.3 million net loss for the three months ended June 30, 2026.
• Increase in general and administrative expenses by 72% for the three months ended June 30, 2026.
• Potential for non-utilization fees if Term A loans are not fully drawn.
• The company continues to require substantial additional capital to finance operations.
• Risk factors associated with drug development, regulatory approvals, and market acceptance remain significant.
• The company has an accumulated deficit of $502.9 million as of June 30, 2026.

Risks

• The company has limited operating history, has incurred substantial net losses, and anticipates continued net losses for the foreseeable future.
• Failure to raise substantial additional capital when needed could force the company to delay, reduce, or eliminate research and development programs.
• The success of the company is entirely dependent on the success of its product candidates, with no guarantee of development completion, regulatory approval, or commercialization.
• Clinical trials are lengthy, expensive, and uncertain, with earlier results not always predictive of future outcomes.
• Competition from other pharmaceutical and biotechnology companies with significant resources is a major risk.
• Potential side effects or safety risks associated with product candidates could lead to trial suspension, abandonment, or delayed approval.
• Reliance on third-party manufacturers and suppliers introduces risks of performance failure, regulatory non-compliance, or supply disruption.
• The company is subject to various legal proceedings, including a shareholder class action complaint.

Future Outlook

The company expects to continue incurring operating losses and negative cash flows to support the development of its product candidates. Management estimates that existing cash, marketable securities, ATM facility proceeds, and available term loans will be sufficient to fund operations for at least the next 12 months. However, the company will need to raise additional capital and faces significant risks related to clinical development, regulatory approvals, and commercialization.

Management Comments

• Management estimates that its existing cash and cash equivalents and available-for-sale marketable securities balances, net proceeds from the sale of shares under the ATM Facility and the term loans available under the Loan Facility with Oxford Finance will be sufficient to fund its operating plan and capital expenditure requirements for at least the next 12 months from the issuance of these condensed financial statements.
• We plan to monitor expenses and raise additional capital through equity or debt financings, strategic alliances and licensing arrangements.
• Our ability to access capital when needed is not assured and if capital is not available to us when, and in the amounts, needed, we could be required to delay, scale back or abandon some or all of our development programs and other operations, which could materially harm our business, financial condition and results of operations.

Industry Context

StockSavvy.ai notes that Kyverna Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on CAR T-cell therapies for autoimmune diseases. The company's progress in clinical trials and regulatory engagement aligns with industry trends, but the significant ongoing investment required for drug development and the inherent risks of the sector are key considerations.

Comparison to Industry Standards

• Kyverna's R&D expenses as a percentage of total operating expenses are typical for a clinical-stage biotechnology company, reflecting the significant investment required for drug development.
• The company's net loss and accumulated deficit are also consistent with industry norms for companies at this stage of development, where revenue generation is minimal or non-existent.
• The use of ATM facilities and debt financing for capital raises is a common strategy employed by biotechnology firms to fund operations and clinical development.
• The pursuit of RMAT and Orphan Drug Designations is a standard practice to accelerate development and potentially gain market exclusivity for therapies targeting serious or rare diseases.

Legal Proceedings

• A shareholder class action complaint was filed in December 2024, alleging material misstatements or omissions in the IPO registration statement and prospectus. An amended complaint was filed, and defendants filed a motion to dismiss. A hearing is scheduled for September 3, 2026.
• A stockholder derivative complaint was filed in May 2025, alleging claims related to the allegations in the securities class action. The derivative actions have been consolidated and stayed pending the disposition of the motion to dismiss in the securities class action.

Related Party Transactions

• The company has a $3.8 million balance presented as current accrued license expense related party payable to Kite Therapeutics, Inc. by December 31, 2026, related to a settlement of an outstanding balance from a license agreement.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity issuances.
• The company's ability to fund operations and clinical trials impacts its long-term viability, affecting investor confidence.
• Successful clinical development and regulatory approval of miv-cel could significantly benefit patients with SPS and gMG by providing new treatment options.
• The amendment to the loan agreement impacts the company's debt obligations and financial flexibility.

Next Steps

• Complete rolling BLA submission for miv-cel in SPS in the fourth quarter of 2026.
• Report 12-month topline data from KYSA-8 for miv-cel in SPS in the third quarter of 2026.
• Complete patient enrollment for the Phase 3 registrational trial of miv-cel in gMG by mid-2027.
• Share longer-term, follow-up Phase 2 topline data in gMG in the third quarter of 2026.
• Provide an update on the PMS development strategy by early 2027.
• Continue advancing activities to enable a successful launch of miv-cel upon approval, including commercial leadership hiring and site activation.

Key Dates

Recommendation

Kyverna Therapeutics is advancing promising CAR T-cell therapies for autoimmune diseases, evidenced by positive clinical trial data and regulatory progress (RMAT designations, BLA submission). However, the company continues to incur substantial losses, requires significant future capital, and faces inherent risks in drug development and commercialization. The recent loan amendment provides some financial flexibility, but the overall risk profile warrants a cautious 'hold' stance until further clinical validation and de-risking of the commercial path are achieved.

Keywords

Loan and Security Agreement Amendment, CAR T-cell therapy, Stiff Person Syndrome, Myasthenia Gravis, Clinical Trials, Biologics License Application, Biotechnology, Drug Development